Skip to main content
SpringerLink
Log in

Neuromuskuläre Störungen beim Intensivpatienten, Critical-illness-Neuropathie und andere neurologische Störungen

  • Chapter
Die Intensivmedizin

  • 2200 Accesses

Auszug

Eine Reihe von Erkrankungen des peripheren Nervensystems, der neuromuskulären Endplatte und der quergestreiften Muskulatur kann durch rasch fortschreitende Lähmung, Ateminsuffizienz und autonome Störungen lebensbedrohlich werden und eine intensivmedizinische Behandlung erfordern. Diese Erkrankungen können Folge einer Störung oder eines Versagens der Impulsfortleitung entlang des Axons, einer neuromuskulären Übertragungsstörung oder einer strukturellen Schädigung von Nerv oder Muskel sein. Die Ursachen sind in · Tabelle 55.1 gezeigt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. The Guillain-Barre Syndrome Study Group (1985) Plasmapheresis and acute Guillain-Barre syndrome. Neurology 35:1096–1104

    Article  Google Scholar 

  2. Al Lozi MT, Pestronk A, Yee WC, Flaris N, Cooper J (1994) Rapidly evolving myopathy with myosin-deficient muscle fibers. Ann Neurol 35: 273–279

    Article  Google Scholar 

  3. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ (2005) Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 142: 439–450

    Article  PubMed  Google Scholar 

  4. Ariga T, Yu RK (2005) Antiglycolipid antibodies in Guillain-Barre syndrome and related diseases: review of clinical features and antibody specificities. J Neurosci Res 80:1–17

    Article  PubMed  CAS  Google Scholar 

  5. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:462–471

    Article  PubMed  CAS  Google Scholar 

  6. Benatar M, Kaminski H (2006) Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev CD005081

    Google Scholar 

  7. Bolton CF (2005) Neuromuscular manifestations of critical illness. Muscle Nerve 32:140–163

    Article  PubMed  Google Scholar 

  8. Braun NM, Arora NS, Rochester DF (1983) Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 38:616–623

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  9. Chalela JA (2001) Pearls and pitfalls in the intensive care management of Guillain-Barre syndrome. Semin Neurol 21:399–405

    Article  PubMed  CAS  Google Scholar 

  10. Cherington M (2004) Botulism: update and review. Semin Neurol 24: 155–163

    Article  PubMed  Google Scholar 

  11. Csurhes PA, Sullivan AA, Green K, Pender MP, McCombe PA (2005) T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 76: 1431–1439

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, van der Meche FG (2001) Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 29:2281–2286

    Article  PubMed  Google Scholar 

  13. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A, Saruhan-Direskeneli G (2007) Clinical comparison of anti-MuSKvs anti-AChR-positive and seronegative myasthenia gracis. Neurology 68:609–611

    Article  PubMed  CAS  Google Scholar 

  14. Dillon FX (2004) Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol 24:83–94

    Article  PubMed  Google Scholar 

  15. Eikermann M, Koch G, Gerwig M, Ochterbeck C, Beiderlinden M, Koeppen S, Neuhauser M, Peters J (2006) Muscleforce and fatigue in patients with sepsis and multiorgan failure. Intensive Care Med 32:251–259

    Article  PubMed  CAS  Google Scholar 

  16. Engel WK, Askanas V (2006) Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 66: S20–S29

    Article  PubMed  Google Scholar 

  17. Engstrom JW (2004) Myasthenia gravis: diagnostic mimics. Semin Neurol 24:141–147

    Article  PubMed  Google Scholar 

  18. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118:289–305

    Article  PubMed  CAS  Google Scholar 

  19. Fletcher SN, Kennedy DD, Ghosh IR, Misra VP, Kiff K, Coakley JH, Hinds CJ (2003) Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 31:1012–1016

    Article  PubMed  Google Scholar 

  20. Fontaine B, Fournier E, Sternberg D, Vicart S, Tabti N (2007) Hypokalemic periodic paralysis: a model for a clinical and research approach to a rare disorder. Neurotherapeutics 4:225–232

    Article  PubMed  CAS  Google Scholar 

  21. Gilchrist JM (2002) Overview of neuromuscular disorders affecting respiratory function. Semin Respir. Crit Care Med 23:191–200

    Google Scholar 

  22. Green DM (2005) Weakness in the ICU: Guillain-Barre Syndrome, Myasthenia Gravis, and Critical Illness Polyneuropathy/Myopathy. Neurologist 11:338–347

    Article  PubMed  Google Scholar 

  23. Gutmann L, Blumenthal D, Gutmann L, Schochet SS (1996) Acute type II myofiber atrophy in critical illness. Neurology 46:819–821

    Article  PubMed  CAS  Google Scholar 

  24. Hain B, Jordan K, Deschauer M, Zierz S (2006) Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 33:575–580

    Article  PubMed  Google Scholar 

  25. Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barre syndrome; Pt I. Muscle Nerve 18:137–153

    Article  PubMed  CAS  Google Scholar 

  26. Henderson RD, Sandroni P, Wijdicks EF (2005) Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol 252: 1235–1237

    Article  PubMed  Google Scholar 

  27. Hughes RA, Cornblath DR (2005) Guillain-Barre syndrome. Lancet 366:1653–1666

    Article  PubMed  CAS  Google Scholar 

  28. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC (2003) Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 61:736–740

    Article  PubMed  CAS  Google Scholar 

  29. Hughes RA, Wijdicks EF, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Sladky JT, Barohn RJ, Stevens JC (2005) Supportive care for patients with guillain-barre syndrome. Arch Neurol 62:1194–1198

    Article  PubMed  Google Scholar 

  30. Hund E (2001) Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 248:929–934

    Article  PubMed  CAS  Google Scholar 

  31. Hund EF, Borel CO, Cornblath DR, Hanley DF, McKhann GM (1993) Intensive management and treatment of severe Guillain-Barre syndrome. Crit Care Med 21:433–446

    Article  PubMed  CAS  Google Scholar 

  32. Illa I (2005) IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 252 Suppl 1:I14-I18

    Google Scholar 

  33. Jander S, Hartung H-P (2006) Aktuelle Aspekte in der Pathogenese, Diagnostik und Therapie der Myasthenia gravis. Akt Neurol 32:3–9

    Article  Google Scholar 

  34. Kelly BJ, Luce JM (1991)The diagnosis and management of neuromuscular diseases causing respiratory failure. Chest 99:1485–1494

    Article  PubMed  CAS  Google Scholar 

  35. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30: 131–156

    Article  PubMed  CAS  Google Scholar 

  36. Köller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343–1356

    Article  PubMed  Google Scholar 

  37. Kung AW (2006) Clinical Review: Thyrotoxic periodic paralysis: a diagnostic challenge. Journal of Clinical Endocrinology & Metabolism 91:2490–2495

    Article  CAS  Google Scholar 

  38. Lacomis D, Petrella JT, Giuliani MJ (1998) Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve 21:610–617

    Article  PubMed  CAS  Google Scholar 

  39. Laroia ST, Zaw KM, Ganti AK, Newman W, Akinwande AO (2002) Amiodarone-induced thyrotoxicosis presenting as hypokalemic periodic paralysis. South Med J 95:1326–1328

    Article  PubMed  Google Scholar 

  40. Latronico N, Guarneri B, Alongi S, Bussi G, Candiani A (1999) Acute neuromuscular respiratory failure after ICU discharge. Report of five patients. Intensive Care Med 25:1302–1306

    Article  CAS  Google Scholar 

  41. Lefaucheur JP, Nordine T, Rodriguez P, Brochard L (2006) Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiat 77:500–506

    Article  PubMed Central  PubMed  Google Scholar 

  42. Lehmann HC, Hartung HP, Hetzel GR, Kieseier BC (2007) Plasmaaustausch als Therapieoption bei neurologischen Erkrankungen. (Plasma exchange as a therapeutic option in neurological disorders.) Nervenarzt 78:166–176

    PubMed  CAS  Google Scholar 

  43. Levin KH (2004) Variants and mimics of Guillain Barre Syndrome. Neurologist 10:61–74

    Article  PubMed  Google Scholar 

  44. Lundberg IE, Alexanderson H (2007) Technology insight: tools for research, diagnosis and clinical assessment of treatment in idiopathic inflammatory myopathies. Nature Clinical Practice. Rheumatology 3:282–290

    Article  PubMed  CAS  Google Scholar 

  45. Lynn DJ, Woda RP, Mendell JR (1994) Respiratory dysfunction in muscular dystrophy and other myopathies. Clin Chest Med 15:661–674

    PubMed  CAS  Google Scholar 

  46. Mahanes D, Lewis R (2004) Weaning of the neurologically impaired patient. Crit Care Nurs Clin North Am 16:387–393

    Article  PubMed  Google Scholar 

  47. Marinelli WA, Leatherman JW (2002) Neuromuscular disorders in the intensive care unit. Crit Care Clin 18:915–929

    Article  PubMed  Google Scholar 

  48. McCarthy N, Giesecke J (2001) Incidence of Guillain-Barre syndrome following infection with Campylobacterjejuni. Am. J Epidemiol 153: 610–614

    Article  PubMed  CAS  Google Scholar 

  49. Mitchell JD, Borasio GD (2007) Amyotrophic lateral sclerosis. Lancet 369:2031–2041

    Article  PubMed  CAS  Google Scholar 

  50. Müllges W, Toyka KV, Hartung H-P (1994) Acute muscular weakness. In: Hacke W, Hanley DF (Hrsg) Neurocritical Care, Berlin, S 307–320

    Google Scholar 

  51. Natarajan N, Weinstein R (2005) Therapeutic apheresis in neurology critical care. J Intensive Care Med 20:212–225

    Article  PubMed  Google Scholar 

  52. Newsom-Davis J (2003) Therapy in myasthenia gravis and LambertEaton myasthenic syndrome. Seminars in Neurology 23:191–198

    Article  PubMed  Google Scholar 

  53. Palmer KM (2006) Abdominal pain due to acute intermittent porphyria: when is the sound of hoof-beats not horses, but zebras? A Case Report. Dimens Crit Care Nurs 25:103–109

    Article  PubMed  Google Scholar 

  54. Rabinstein AA (2005) Update on respiratory management of critically ill neurologic patients. Curr Neurol Neurosci Rep 5:476–482

    Article  PubMed  Google Scholar 

  55. Raju R, Dalakas MC (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128:1887–1896

    Google Scholar 

  56. Sanap MN, Worthley LI (2002) Neurologic complications of critical illness: part II. Polyneuropathies and myopathies. Crit Care Resusc 4: 133–140

    PubMed  CAS  Google Scholar 

  57. Schneider-Gold C, Hartung HP, Gold R (2006) Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases. Muscle Nerve 34(3): 284–291

    Article  PubMed  CAS  Google Scholar 

  58. Schroeter M, Hartung H-P (2005) Epidemiologie, Diagnostik und Differenzialdiagnose der diabetischen Polyneuropathie. Psychoneuro 31: 569–574

    Article  Google Scholar 

  59. Stangel M, Gold R (2004) Use of IV immunoglobulins in neurology. Evidence-based consensus. Nervenarzt 75:801–816

    Article  PubMed  CAS  Google Scholar 

  60. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, Brannagan TH, Fink ME, Rowland LP (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48:1253–1260

    Article  PubMed  CAS  Google Scholar 

  61. Wijdicks EF, Henderson RD, McClelland RL (2003) Emergency intubation for respiratory failure in Guillain-Barre syndrome. Arch Neurol 60: 947–948

    Article  PubMed  Google Scholar 

  62. Yeh JH, Chen WH, Chiu HC (2003) Predicting the course of myasthenic weakness following double filtration plasmapheresis. Acta Neurol Scand 108:174–178

    Article  PubMed  CAS  Google Scholar 

  63. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M (2004) Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 101:11404–11409

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik, Universitätsklinikum Düsseldorf, Moorenstr. 5, D-40225, Düsseldorf

    H.-P. Hartung (Prof. Dr.)

  2. Neurologische Klinik Heinrich-Heine-Universität, Moorenstr. 5, D-40225, Düsseldorf

    B.C. Kieseier (Prof. Dr.)

  3. Klinik u. Poliklinik für Neurologie, Klinikum der Universität Köln, Joseph-Stelzmann-Str. 9, D-50931, Köln

    M. Schroeter (Priv.-Doz. Dr.)

Authors
  1. H.-P. Hartung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B.C. Kieseier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Schroeter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kiefernweg 2, 37120, Bovenden

    Hilmar Burchardi FRCA

  2. Klinik für Anaesthesiologie und Intensivmedizin, Universitätskliniken des Saarlandes, Gebäude 57, 66421, Homburg/Saar

    Reinhard Larsen

  3. Klinik für Intensivmedizin, HELIOS Klinikum Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin

    Ralf Kuhlen

  4. Chirurgische Klinik u. Poliklinik Klinikum Großhadern, LMU München, Marchioninistr. 15, 81377, München

    Karl-Walter Jauch

  5. Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg, 93042, Regensburg

    Jürgen Schölmerich

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Hartung, HP., Kieseier, B., Schroeter, M. (2008). Neuromuskuläre Störungen beim Intensivpatienten, Critical-illness-Neuropathie und andere neurologische Störungen. In: Burchardi, H., Larsen, R., Kuhlen, R., Jauch, KW., Schölmerich, J. (eds) Die Intensivmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72296-0_55

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72296-0_55

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72295-3

  • Online ISBN: 978-3-540-72296-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation